Relación del tratamiento y coste con la ganancia de agudeza visual en la degeneración macular asociada a la edad

Fundamento. Relacionar la ganancia de agudeza visual (AV) con el coste asistencial y de tratamiento con terapia anti-factor de crecimiento endotelial vascular (antiVEGF) en pacientes diagnosticados de degeneración macular asociada a la edad exudativa (DMAE exudativa). Pacientes y métodos. Estudio observacional, longitudinal, retrospectivo, de pacientes ≥ 50 años diagnosticados de DMAE exudativa, con agudeza visual logMAR entre 0,6 y 0,06, en seguimiento y tratamiento en nuestro hospital de tercer nivel entre el 01/01/2014 y el 31/12/2018. Resultados. Se incluyeron 778 pacientes, 62,2% mujeres y media de edad 79,83±7,94 años, con 957 ojos con DMAE exudativa. La AV final global (0,65±0,45) aumentó un 3,2% respecto de la inicial. El 60,3% de los ojos recibieron antiVEGF con ranibizumab, el 10,2% con aflibercept y el 29,5% con ambos (mixto). El grupo mixto incrementó significativamente la AV respecto de la inicial, sin diferencias entre grupos. Aunque el seguimiento/tratamiento fue más largo para el grupo mixto, este recibió menos inyecciones antiVEGF y tomografías de coherencia óptica (OCT). El gasto total por año y ojo tratado fue de 1.972,7€±824,5; los costes fueron mayores para visita, OCT y tratamiento en el grupo de aflibercept, y menores para angiografías con fluoresceína, tratamiento antiVEGF y costes totales en el grupo mixto. La ganancia decimal de AV tuvo un coste de 872€±1.077,7 sin diferencias significativas entre grupos. Conclusiones. Los tratamientos antiVEGF con ranibizumab, aflibercept y ambos mantuvieron la AV en pacientes con DMAE exudativa. En general, los costes asistenciales y de tratamiento fueron menores en el grupo que recibió ambos fármacos

Comparison of visual and optical quality of monofocal versus multifocal intraocular lenses

Postprint (author's final draft

Controlled release for formulations

In this sense, we herein describe, for the first time, the first report of immobilization of a non-ionic drug (dexamethasone) on a Laponite clay, wherein the clay is not used as a component of a polyurethane composite.Peer reviewedUniversidad de Zaragoza, Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Consejo Superior de Investigaciones Científicas (CSIC)A1 Solicitud de patente con informe sobre el estado de la técnic

Correction: Study of Association between Pre-Senile Cataracts and the Polymorphisms rs2228000 in XPC and rs1042522 in p53 in Spanish Population.

[This corrects the article DOI: 10.1371/journal.pone.0156317.]

Polymorphism genotype distribution (rs 1042522) in P53 gene in pre-senile and senile cataracts groups.

<p>Polymorphism genotype distribution (rs 1042522) in P53 gene in pre-senile and senile cataracts groups.</p

Polymorphism genotype distribution (rs 2228000) in XPC gene in the senile cataracts group and the group with no cataract.

<p>Polymorphism genotype distribution (rs 2228000) in XPC gene in the senile cataracts group and the group with no cataract.</p

Polymorphism genotype distribution (rs 2228000) in XPC gene in pre-senile and senile cataracts groups.

<p>Polymorphism genotype distribution (rs 2228000) in XPC gene in pre-senile and senile cataracts groups.</p

Polymorphism genotype distribution (rs 1042522) in P53 gene in the pre-senile cataract group and the group with no cataract.

<p>Polymorphism genotype distribution (rs 1042522) in P53 gene in the pre-senile cataract group and the group with no cataract.</p

Study of Association between Pre-Senile Cataracts and the Polymorphisms rs2228000 in XPC and rs1042522 in p53 in Spanish Population.

PURPOSE:To determine if the presence of certain polymorphisms in the DNA repair gene XPC and the apoptosis inductor gene p53 is associated with pre-senile cataract development. METHODS:We have performed a retrospective study over three groups of patients. The group with pre-senile cataract formed by 72 patients younger than 55 with cataract surgery. The group with senile cataract formed by 101 patients older than 55 with cataract surgery. The group without cataract was formed by 42 subjects older than 55 without lens opacities. We analyzed the presence of SNP rs2228000 from XPC and rs1042522 from p53; and the relationship between risk factors such as smoking, alcohol intake, hypertension or diabetes. RESULTS:The comparison of the genotype distribution in XPC, within the different groups, did not show any statistically significant association in any of our analysis (p>0,05). The comparison of the genotype distribution in p53 within the different groups did not show any statistically significant association (p>0,05); except for the comparison between the pre-senile cataract group and the group with senile cataract where the genotype Pro/Pro (C/C) in the recessive inheritance model showed a higher risk for developing pre-senile cataract (p = 0,031; OR = 1.04-15.97). This association decreased when we performed the analysis adjusting by the studied risk factors (p = 0.056). CONCLUSIONS:Allelic variants in the gene XPC are not associated with an increased risk for developing pre-senile cataract. The presence of the genotype Pro/Pro in p53 might be associated with a major risk for developing pre-senile cataract

Polymorphism genotype distribution (rs 1042522) in P53 gene, in the group with senile cataract and the group with no cataract.

<p>Polymorphism genotype distribution (rs 1042522) in P53 gene, in the group with senile cataract and the group with no cataract.</p